Antitumor Effects of Human Lymphoblastoid Interferon on Advanced Renal Cell Carcinoma

Fujita, Tamio; Asano, Haruyoshi; Naide, Yorio; Ono, Yoshinari; Ohshima, Shinichi; Suzuki, Kazuo; Aso, Yoshio; Ariyoshi, Y; Fukushima, Masanori; K, Ota

doi:10.1016/s0022-5347(17)42380-9

Cited by 27 publications

(4 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although, of the IFNs, IFN-a seems to be the most active one for that purpose, its effectiveness is usually limited to lung métastasés and its effect on laryngeal metastasis has never been reported [7][8][9][10][11]. Our case revealed that a metastatic tumor on the surface of the base of the tongue disappeared both grossly and microscopically 1 month after the initiation of IFN-a therapy, despite progression of other metastatic foci, including the lung.…”

Section: Case Reportmentioning

confidence: 64%

Disappearance of Metastatic Renal Cell Carcinoma to the Base of the Tongue after Systemic Administration of Interferon-Alpha

Shibayama¹,

Hasegawa²,

Nakamura³

et al. 1993

Eur Urol

View full text Add to dashboard Cite

Section: Case Reportmentioning

confidence: 64%

Disappearance of Metastatic Renal Cell Carcinoma to the Base of the Tongue after Systemic Administration of Interferon-Alpha

Shibayama¹,

Hasegawa²,

Nakamura³

et al. 1993

Eur Urol

View full text Add to dashboard Cite

“…Metastatic renal cell carcinoma (mRCC) has a very poor prognosis, and it has been reported that the 5‐year patient survival rate is only 5%–30% (1–3). Cytoreductive nephrectomy and subsequent cytokine therapy improve the prognosis of patients with mRCC (4–6). Recently, cytoreductive nephrectomy has been performed laparoscopically, and its operative record has been comparable to that of open cytoreductive nephrectomy (7,8).…”

Section: Introductionmentioning

confidence: 99%

Laparoscopic cytoreductive nephrectomy with cytokine therapy for metastatic renal cell carcinomas compared with open nephrectomy

Fujita

Hattori

Kinukawa

et al. 2010

Asian J Endoscop Surgery

View full text Add to dashboard Cite

Introduction: We retrospectively reviewed and compared the operation records and long‐term results of patients with metastatic renal cell carcinoma (mRCC) who underwent laparoscopic cytoreductive nephrectomy and those who underwent open procedure. Methods: A total of 75 patients with mRCC who underwent cytoreductive nephrectomy between 1997 and 2007 were studied: 23 patients in the laparoscopy group (LCN group) and 52 in the open group (OCN group). Most patients received interferon‐based cytokine therapy after surgery. Patients with tumor thrombus in the inferior vena cava were excluded from this study. Results: Operating time in the LCN group was significantly longer than in the OCN group (320.3 min vs 269.6 min, P=0.049). Blood loss was less in the LCN group (527.8 ml) than in the OCN group (1372.3 ml, P=0.072). Convalescence was shorter in the LCN group (18.1 d) than in the OCN group (32.9 d, P<0.0001). Median follow‐up periods were 15 months (range 2–110 months) and 17 months (range 1–103 months) in the LCN group and OCN group, respectively. There was no statistically significant difference between the two groups with regard to disease‐specific patient survival and progression‐free survival. Conclusions: Laparoscopic cytoreductive nephrectomy is a feasible alternative for patients with mRCC because its benefits include less blood loss and shorter convalescence. In addition, the long‐term oncological results of laparoscopic cytoreductive nephrectomy are comparable to those of the open procedure.

show abstract

“…Modulation of HLA antigens was studied in the nude mouse, hence 1-cell-mediated effector mechanisms cannot explain the good correlation between inducibility and response. Nonetheless, our studies indicate that the extent of modulation of HLA-class4 and -11 can serve as predictive marker for response t o cytokine therapy, which may serve as a valuable criterion for inclusion of patients in cytokine treatment regimens.In the management of metastatic renal-cell carcinoma, cytokine therapy has proven to be effective in approximately 15% of patients (Fujita et al, 1988;Garnick et al, 1988;Sarna et al, 1987;Trump et al, 1990). In the further implementation of this still experimental therapeutic modality, two questions are considered relevant, i.e., how can optimal cytokine treatment combination and dosage be determined?…”

mentioning

confidence: 99%

“…In the management of metastatic renal-cell carcinoma, cytokine therapy has proven to be effective in approximately 15% of patients (Fujita et al, 1988;Garnick et al, 1988;Sarna et al, 1987;Trump et al, 1990). In the further implementation of this still experimental therapeutic modality, two questions are considered relevant, i.e., how can optimal cytokine treatment combination and dosage be determined?…”

mentioning

confidence: 99%

HLA‐class‐I and‐class‐II expression on renal tumor xenografts and the relation to sensitivity for α‐IFN, γ‐IFN and TNF

Beniers

Peelen

Debruyne

et al. 1991

Intl Journal of Cancer

View full text Add to dashboard Cite

In this study we evaluated the usefulness of the histocompatibility leucocyte antigen (HLA) class-I and class-II expression on renal-cell carcinoma (RCC) xenografts as predictive markers for response to cytokine therapy. Eight different RCC xenografts growing in BALBC nu/nu mice were treated with 0.5 or 5.0 ng/g recombinant human alpha- or gamma-interferon (IFN), or 500 ng/g recombinant human tumor necrosis factor (TNF). Modulation of HLA class-I, -II expression was evaluated immunohistochemically using the monoclonal antibodies (MAbs) W6.32 and B8.11.2 and at the mRNA level using the plasmids pDP001 and DR alpha 120. HLA class-I expression in all lines was upregulated by alpha- and gamma-IFN and was highest in the high-IFN-dose-treated tumors. TNF also stimulated HLA-class-I expression and up-regulated class-I expression still further when combined with IFN. Highest up-regulation of HLA-class-I in all tumors was measured in the alpha-IFN-5.0/TNF-500-ng/g-treated mice, although this was not necessarily the treatment regimen resulting in the most pronounced effect on tumor growth. Hence, maximum upregulation of class-I antigens at a given regimen was not always indicative for the highest achievable anti-tumor effect. HLA-class-II expression which was present on only 3 of the untreated tumors was up-regulated by both alpha and gamma-IFN. TNF itself did not up-regulate class-II expression but enhanced the class-II expression on the alpha-IFN-treated tumors but not on the gamma-IFN-treated tumors. Irrespective of the basic expression level, inducibility of both HLA-class-I and -class-II antigens appear to be correlated to the direct effects on growth of renal-tumor xenografts towards alpha-IFN, gamma-IFN and TNF. Modulation of HLA antigens was studied in the nude mouse, hence T-cell-mediated effector mechanisms cannot explain the good correlation between inducibility and response. Nonetheless, our studies indicate that the extent of modulation of HLA-class-I and -II can serve as predictive marker for response to cytokine therapy, which may serve as a valuable criterion for inclusion of patients in cytokine treatment regimens.

show abstract

Antitumor Effects of Human Lymphoblastoid Interferon on Advanced Renal Cell Carcinoma

Cited by 27 publications

References 6 publications

Disappearance of Metastatic Renal Cell Carcinoma to the Base of the Tongue after Systemic Administration of Interferon-Alpha

Disappearance of Metastatic Renal Cell Carcinoma to the Base of the Tongue after Systemic Administration of Interferon-Alpha

Laparoscopic cytoreductive nephrectomy with cytokine therapy for metastatic renal cell carcinomas compared with open nephrectomy

HLA‐class‐I and‐class‐II expression on renal tumor xenografts and the relation to sensitivity for α‐IFN, γ‐IFN and TNF

Contact Info

Product

Resources

About